EV/EBITDA - Epizyme Inc (F:EPE) - Alpha Spread
E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33% Market Closed
Market Cap: 92.2B EUR
Have any thoughts about
Epizyme Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-548.8
Current
-526.3
Median
5.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-548.8
=
Enterprise Value
94.2B EUR
/
EBITDA
-190.9m USD
All Countries
Close
EBITDA Growth
US
E
Epizyme Inc
F:EPE
Average EV/EBITDA: 47.3
Negative Multiple: -548.8
N/A
US
Abbvie Inc
NYSE:ABBV
15.7
28%
US
Amgen Inc
NASDAQ:AMGN
20.1
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.8
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
AU
CSL Ltd
ASX:CSL
22.3
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -62.8 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 236.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
210.8
N/A
NL
argenx SE
NASDAQ:ARGX
Negative Multiple: -90.7 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A

See Also

Discover More